These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26399763)

  • 1. Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan.
    Wang CC; Lin CL; Hsieh TY; Tseng KC; Peng CY; Su TH; Yang SS; Hsu YC; Chen TM; Kao JH
    Hepatol Int; 2016 Mar; 10(2):294-301. PubMed ID: 26399763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
    Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
    Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.
    Pan HY; Pan HY; Song WY; Zheng W; Tong YX; Yang DH; Dai YN; Chen MJ; Wang MS; Huang YC; Zhang JJ; Huang HJ
    J Viral Hepat; 2017 Nov; 24 Suppl 1():29-35. PubMed ID: 29082652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice.
    Tsai MC; Lee CM; Chiu KW; Hung CH; Tung WC; Chen CH; Tseng PL; Chang KC; Wang JH; Lu SN; Yen YH; Hu TH
    J Antimicrob Chemother; 2012 Mar; 67(3):696-9. PubMed ID: 22174039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine.
    Zhang Y; Lian JQ; Li Y; Wang JP; Huang CX; Bai XF; Wang JP
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):814-9. PubMed ID: 23406845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
    Lu JJ; Liu K; Ma YJ; Wang J; Chen EQ; Tang H
    J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P; Lenci I; di Paolo D; Demelia L; Sorbello O; Nosotti L; Angelico M
    Antivir Ther; 2013; 18(1):57-64. PubMed ID: 22872648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil.
    Li Y; Zhang Y; Wang JP; Lian JQ; Bai XF
    J Viral Hepat; 2013 Apr; 20 Suppl 1():46-51. PubMed ID: 23458524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B.
    Gane EJ; Wang Y; Liaw YF; Hou J; Thongsawat S; Wan M; Moon YM; Jia J; Chao YC; Niu J; Leung N; Samuel D; Hsu CW; Bao W; Lopez P; Avila C
    Liver Int; 2011 May; 31(5):676-84. PubMed ID: 21457439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels.
    Lv GC; Ma WJ; Ying LJ; Jin X; Zheng L; Yang YD
    World J Gastroenterol; 2010 Aug; 16(32):4095-9. PubMed ID: 20731026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world application of the roadmap model in chronic hepatitis B patients with telbivudine therapy.
    Yu HC; Lin KH; Hsu PI; Tsay FW; Wang HM; Tsai TJ; Lai KH
    Clin Ther; 2013 Sep; 35(9):1386-99. PubMed ID: 24054706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telbivudine therapy for chronic hepatitis B: A journey to identify super-responders and to optimize treatment using the roadmap model.
    Kao JH; Asselah T; Dou XG; Hamed K
    J Gastroenterol Hepatol; 2017 Jan; 32(1):73-81. PubMed ID: 27515408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at week 24.
    Hsu CW; Chao YC; Lee CM; Chang TT; Chen YC
    BMC Gastroenterol; 2012 Dec; 12():178. PubMed ID: 23234302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An observational study to evaluate the safety and efficacy of telbivudine in adults with chronic hepatitis B.
    Sulaiman A; Lesmana LA; Nafrialdi ; Helyanna
    Acta Med Indones; 2014 Jan; 46(1):38-43. PubMed ID: 24760807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome.
    Seto WK; Lai CL; Fung J; Wong DK; Yuen JC; Hung IF; Yuen MF
    J Hepatol; 2011 Sep; 55(3):522-528. PubMed ID: 21147187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
    Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study.
    Huang Z; Zhao Z; Zheng Y; Peng L; Lin C; Deng H; Gao Z
    J Viral Hepat; 2013 Apr; 20 Suppl 1():52-7. PubMed ID: 23458525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum HBV DNA level at week 12 is superior to viral response at week 24 in predicting long-term treatment outcome of telbivudine for chronic hepatitis B patients.
    Lü W; Yang HH; Fan YM; Li T; Zhang LF; Mui C; Fan HW; Zhou BT; Liu ZY; Ng H; Liu XQ
    Chin Med J (Engl); 2013 Jun; 126(12):2333-6. PubMed ID: 23786949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine.
    Safadi R; Xie Q; Chen Y; Yin YK; Wei L; Hwang SG; Zuckerman E; Jia JD; Lopez P
    Liver Int; 2011 May; 31(5):667-75. PubMed ID: 21040410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated serum interleukin-38 level at baseline predicts virological response in telbivudine-treated patients with chronic hepatitis B.
    Wang HJ; Jiang YF; Wang XR; Zhang ML; Gao PJ
    World J Gastroenterol; 2016 May; 22(18):4529-37. PubMed ID: 27182162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.